{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-374328","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2026-08-28T20:05:51+00:00","discovered_at":"2026-08-28T20:08:03.231135+00:00","generated_at":"2026-08-28T20:08:19.795780+00:00","sec_items":["1.01","1.03","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Sangamo sells ST-920 Fabry gene therapy to PTC for $111M cash plus $100M milestones in Chapter 11","bullets":["Sangamo filed Chapter 11 on June 23, 2026; PTC won auction for ST-920 assets.","Deal: $111M cash at closing plus up to $100M milestones; $80M on FDA accelerated approval, $20M on full approval.","Bankruptcy Court hearing to approve sale scheduled for September 10, 2026; closing by October 15, 2026.","ST-920 is AAV gene therapy for Fabry disease; PTC assumes specified liabilities.","Stock delisted from Nasdaq May 5, 2026; now trades OTC as SGMOQ."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-374328","json":"https://secwatch.observer/filing/0001193125-26-374328.json","markdown":"https://secwatch.observer/filing/0001193125-26-374328.md","text":"https://secwatch.observer/filing/0001193125-26-374328.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000119312526374328/0001193125-26-374328-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000119312526374328/d116527d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-28T20:08:19.795780+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}